Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Ferrannini

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Diabetes Research and Clinical Practice|November 29, 2021
Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registryGiulia Ferrannini, Dirk De Bacquer, Viveca Gyberg, et al.
Frontiers in Cardiovascular Medicine|February 21, 2022
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in HumansEle Ferrannini, Maria Laura Manca, Giulia Ferrannini, et al.
Scandinavian Cardiovascular Journal : SCJ|August 17, 2022
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANKGiulia Ferrannini, Mariam Almosawi, Kåre Buhlin, et al.
Diabetes Research and Clinical Practice|November 6, 2022
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)Magnus Lundin, Giulia Ferrannini, Linda Mellbin, et al.
Scandinavian Cardiovascular Journal : SCJ|February 1, 2023
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trialGiulia Ferrannini, Juan M Maldonado, Sohini Raha, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|April 19, 2026
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registryGiulia Ferrannini, Francesca Musella, Lina Benson, et al.
Cardiovascular Diabetology|December 2, 2025
Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registriesAurora Merolla, Valeria Valente, Christian Basile, et al.
Cardiovascular Diabetology|February 12, 2021
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveysGiulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, et al.
Cardiovascular Drugs and Therapy|October 17, 2020
Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V RegistryPieter Vynckier, Giulia Ferrannini, Lars Rydén, et al.
Diabetes Care|June 30, 2022
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V PopulationGiulia Ferrannini, Dirk De Bacquer, Iris Erlund, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Diabetes Research and Clinical Practice|November 29, 2021
Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registryGiulia Ferrannini, Dirk De Bacquer, Viveca Gyberg, et al.
Frontiers in Cardiovascular Medicine|February 21, 2022
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in HumansEle Ferrannini, Maria Laura Manca, Giulia Ferrannini, et al.
Scandinavian Cardiovascular Journal : SCJ|August 17, 2022
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANKGiulia Ferrannini, Mariam Almosawi, Kåre Buhlin, et al.
Diabetes Research and Clinical Practice|November 6, 2022
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)Magnus Lundin, Giulia Ferrannini, Linda Mellbin, et al.
Scandinavian Cardiovascular Journal : SCJ|February 1, 2023
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trialGiulia Ferrannini, Juan M Maldonado, Sohini Raha, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|April 19, 2026
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registryGiulia Ferrannini, Francesca Musella, Lina Benson, et al.
Cardiovascular Diabetology|December 2, 2025
Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registriesAurora Merolla, Valeria Valente, Christian Basile, et al.
Cardiovascular Diabetology|February 12, 2021
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveysGiulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, et al.
Cardiovascular Drugs and Therapy|October 17, 2020
Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V RegistryPieter Vynckier, Giulia Ferrannini, Lars Rydén, et al.
Diabetes Care|June 30, 2022
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V PopulationGiulia Ferrannini, Dirk De Bacquer, Iris Erlund, et al.
Pageof 5